Activin receptor type-1 (ALK2) (ALK2)

Activin receptor type-1 (ALK2), encoded by the ACVR1 gene, is a type I transmembrane serine/threonine kinase receptor within the TGF-beta/BMP superfamily [3, 6]. It is a central mediator of the bone morphogenetic protein (BMP) signaling pathway, which is essential for embryonic development, skeletal formation, and tissue homeostasis [4, 7]. Upon activation by BMP ligands, ALK2 phosphorylates SMAD1/5/8 proteins, which then translocate to the nucleus to regulate the transcription of genes involved in osteogenesis and cell differentiation [2, 8]. Gain-of-function mutations in ALK2, particularly the R206H substitution, are the primary cause of Fibrodysplasia Ossificans Progressiva (FOP), a devastating condition characterized by progressive heterotopic ossification [3, 13]. Furthermore, somatic mutations in ALK2 have been identified in Diffuse Intrinsic Pontine Glioma (DIPG), an aggressive and lethal pediatric brainstem tumor [4, 10]. Therapeutic development focuses on small molecule inhibitors and monoclonal antibodies that target the ALK2 kinase domain or block ligand binding to restore normal signaling [7, 11]. Key challenges in drug development include achieving selectivity over other ALK family members to avoid off-target effects like cardiac toxicity [14].

Other names

ACVR1ACTRIACVR1AACVRLK2ALK2FOPSKR1TSRI

ALK2 inhibitors primarily function through ATP-competitive inhibition of the kinase domain, which prevents the phosphorylation of downstream SMAD1/5/8 proteins [2, 8, 9]. Monoclonal antibodies target the extracellular domain to block ligand-induced receptor activation and heterotetramer formation [8, 11].